Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Purpose
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumors has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Conditions
- Childhood Extracranial Germ Cell Tumor
- Extragonadal Embryonal Carcinoma
- Germ Cell Tumor
- Malignant Germ Cell Tumor
- Malignant Ovarian Teratoma
- Stage I Ovarian Choriocarcinoma
- Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7
- Stage I Ovarian Teratoma AJCC v6 and v7
- Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7
- Stage I Testicular Choriocarcinoma AJCC v6 and v7
- Stage I Testicular Embryonal Carcinoma AJCC v6 and v7
- Stage I Testicular Seminoma AJCC v6 and v7
- Stage I Testicular Yolk Sac Tumor AJCC v6 and v7
- Stage II Ovarian Choriocarcinoma
- Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7
- Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7
- Stage II Testicular Choriocarcinoma AJCC v6 and v7
- Stage II Testicular Embryonal Carcinoma AJCC v6 and v7
- Stage II Testicular Yolk Sac Tumor AJCC v6 and v7
- Stage III Ovarian Choriocarcinoma
- Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7
- Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7
- Stage III Testicular Choriocarcinoma AJCC v6 and v7
- Stage III Testicular Embryonal Carcinoma AJCC v6 and v7
- Stage III Testicular Yolk Sac Tumor AJCC v6 and v7
- Stage IV Ovarian Choriocarcinoma
- Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7
- Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7
- Testicular Mixed Choriocarcinoma and Embryonal Carcinoma
- Testicular Mixed Choriocarcinoma and Teratoma
- Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Eligibility
- Eligible Ages
- All ages
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT [all sites]) - Standard risk 1: Patient must be < 11 years of age at enrollment - Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment - Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with metastatic germ cell tumor (stage II or higher); histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment except for those who were initially diagnosed with stage I non-seminoma malignant GCT and later recur during observation post surgery off study; for these patients, if elevated tumor markers rise to > 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart, a diagnostic biopsy is not required for enrollment - Low risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I, Federation of Gynecology and Obstetrics (FIGO) stage IA and IB; grade: 2 or 3; histology: pure immature teratoma (may contain microscopic foci of yolk sac tumor), mixed immature and mature teratoma, (no pathological evidence of MGCT); tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; all ages - Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA, IB and IS; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages - Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; AJCC testicular stage IA IB, and IS; histology: must contain at least one of the following: may contain immature/mature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages - Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC, FIGO stage II-IV (International Germ Cell Consensus Classification [IGCCC] criteria DO NOT apply); histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) < 11 - Standard risk 2 (SR2) - Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25 - Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; tumor markers: must be IGCCC good risk; post op: alpha-FP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL and lactate dehydrogenase (LDH) < 3.0 x normal; age (years) >= 11 and < 25 - Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25 - Notes: - IGCCC criteria only apply to SR2 patients with a testicular primary tumor - Use post-op tumor marker levels to determine IGCCC risk group - Stage 1 seminoma patients are not eligible for the standard risk arms of the study - For the low risk stage I non-seminoma MGCT and the standard risk arms, components of yolk sac tumor, embryonal carcinoma, or choriocarcinoma can be mixed with other forms of GCT, such as seminoma or mature or immature teratoma; if yolk sac tumor is the only malignant component present, then it must be deemed by the pathologist to be greater than a "microscopic component" of yolk sac tumor - Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age - Organ function requirements apply ONLY to patients who will receive chemotherapy (SR1 and SR2 patients) - Adequate renal function defined as: - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to enrollment) OR - A serum creatinine based on age/gender as follows (within 7 days prior to enrollment): (mg/dL) - 1 month to < 6 months male: 0.4 female: 0.4 - 6 months to < 1 year male: 0.5 female: 0.5 - 1 to < 2 years male: 0.6 female: 0.6 - 2 to < 6 years male: 0.8 female: 0.8 - 6 to < 10 years male: 1 female: 1 - 10 to < 13 years male: 1.2 female: 1.2 - 13 to < 16 years: male: 1.5 female: 1.4 - >= 16 years male: 1.7 female: 1.4 - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) - Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age (for the purpose of this study, the ULN for SGPT is 45 U/L) (within 7 days prior to enrollment) - Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3 (within 7 days prior to enrollment) AND - Platelet count >= 100,000/mm^3 (within 7 days prior to enrollment) - Patients enrolling on the standard risk arms must be medically fit to receive protocol treatment and with no contraindications to protocol treatment - Eligibility criteria to participate in the pilot study of the AYA-Hears instrument (patient reported outcomes [PROs] of ototoxicity) Note: participants in group 1 will not receive AGCT1531 protocol-directed therapy; all other AYA-HEARS patients must be enrolled on the AGCT1531 SR2 arm in order to participate - >= 11 and < 25 years old at enrollment - Able to fluently speak and read English - Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor - Followed for cancer or survivorship care at one of the following institutions: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Dana Farber/Harvard Cancer Center - Hospital for Sick Children - Children's Hospital of Eastern Ontario - Oregon Health and Science University - Seattle Children's Hospital - Yale University
Exclusion Criteria
- Patients with any diagnoses not listed including: - Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection) - Pure dysgerminoma - Pure mature teratoma - Pure immature teratoma COG stage I, grade I - Pure immature teratoma COG stage I, grade 2,3 with alpha-fetoprotein (AFP) >= 1000 ng/mL - Pure immature teratoma COG stage II - IV or FIGO stage IC to IV - "Poor risk" GCT (age >= 11 years old and COG stage IV ovarian, COG stage III or IV EG, or IGCCC intermediate or poor risk testicular), or - Primary central nervous system (CNS) germ cell tumor - Germ cell tumor with somatic malignant transformation - Spermatocytic seminoma - Patients must have had no prior systemic therapy for the current cancer diagnosis - Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain [stage IV disease] would be considered poor risk and therefore not eligible for this trial) - Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial - Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients]) - Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients]) - Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Arm I (bleomycin, carboplatin, etoposide) |
Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. |
|
Experimental Arm II (bleomycin, etoposide, cisplatin) |
Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. |
|
Experimental Arm III (bleomycin, etoposide, carboplatin) |
Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. |
|
Experimental Arm IV (bleomycin, etoposide, cisplatin) |
Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. |
|
Experimental Low-Risk (observation) |
Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. |
|
Recruiting Locations
Birmingham, Alabama 35233
Mobile, Alabama 36604
Site Public Contact
800-388-8721
Anchorage, Alaska 98508
Anchorage, Alaska 99504
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Kingman, Arizona 86401
Mesa, Arizona 85202
Site Public Contact
480-412-3100
Phoenix, Arizona 85016
Site Public Contact
602-546-0920
Little Rock, Arkansas 72202-3591
Site Public Contact
501-364-7373
Little Rock, Arkansas 72205
Anaheim, California 92806
Arroyo Grande, California 93420
Bellflower, California 90706
Burbank, California 91505
Downey, California 90242
Site Public Contact
626-564-3455
Fontana, California 92335
La Jolla, California 92093
Loma Linda, California 92354
Site Public Contact
909-558-4050
Long Beach, California 90806
Site Public Contact
562-933-5600
Los Angeles, California 90027
Site Public Contact
323-361-4110
Los Angeles, California 90027
Los Angeles, California 90048
Site Public Contact
310-423-8965
Los Angeles, California 90095
Site Public Contact
310-825-6708
Madera, California 93636
Napa, California 94558
Site Public Contact
707-521-3830
Oakland, California 94609
Oakland, California 94611
Orange, California 92868
Palo Alto, California 94304
Sacramento, California 95817
Site Public Contact
916-734-3089
San Diego, California 92108
San Diego, California 92123
Site Public Contact
858-966-5934
San Diego, California 92134
Site Public Contact
619-532-8712
San Francisco, California 94158
Santa Rosa, California 95403
Site Public Contact
707-521-3830
Santa Rosa, California 95405
Site Public Contact
707-521-3830
Aurora, Colorado 80045
Denver, Colorado 80218
Site Public Contact
303-839-6000
Hartford, Connecticut 06106
Site Public Contact
860-545-9981
New Haven, Connecticut 06520
Wilmington, Delaware 19803
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20010
Fort Lauderdale, Florida 33316
Fort Myers, Florida 33908
Gainesville, Florida 32610
Hollywood, Florida 33021
Jacksonville, Florida 32207
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33155
Site Public Contact
888-624-2778
Miami, Florida 33176
Site Public Contact
786-596-2000
Orlando, Florida 32803
Orlando, Florida 32806
Orlando, Florida 32827
Pensacola, Florida 32504
Saint Petersburg, Florida 33701
Tampa, Florida 33606
Tampa, Florida 33607
West Palm Beach, Florida 33407
Site Public Contact
561-881-2815
Atlanta, Georgia 30322
Augusta, Georgia 30912
Macon, Georgia 31201
Savannah, Georgia 31404
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Honolulu, Hawaii 96859
Site Public Contact
808-433-6336
Boise, Idaho 83712
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83686
Twin Falls, Idaho 83301
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Site Public Contact
773-880-4562
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Eureka, Illinois 61530
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Highland Park, Illinois 60035
Site Public Contact
847-570-2109
Kewanee, Illinois 61443
Macomb, Illinois 61455
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Oak Lawn, Illinois 60453
Site Public Contact
847-723-7570
Ottawa, Illinois 61350
Park Ridge, Illinois 60068
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peoria, Illinois 61637
Site Public Contact
888-226-4343
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Washington, Illinois 61571
Indianapolis, Indiana 46202
Site Public Contact
800-248-1199
Indianapolis, Indiana 46260
Ankeny, Iowa 50023
Site Public Contact
515-282-2921
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Creston, Iowa 50801
Des Moines, Iowa 50309
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
West Des Moines, Iowa 50266
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40202
New Orleans, Louisiana 70118
New Orleans, Louisiana 70121
Bangor, Maine 04401
Site Public Contact
207-973-4274
Portland, Maine 04102
Site Public Contact
207-885-7565
Scarborough, Maine 04074
Scarborough, Maine 04074
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Baltimore, Maryland 21215
Baltimore, Maryland 21287
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Boston, Massachusetts 02111
Boston, Massachusetts 02114
Site Public Contact
877-726-5130
Boston, Massachusetts 02215
Site Public Contact
877-442-3324
Springfield, Massachusetts 01199
Worcester, Massachusetts 01655
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Detroit, Michigan 48201
East Lansing, Michigan 48824
Site Public Contact
517-975-9547
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49048
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Reed City, Michigan 49677
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Minneapolis, Minnesota 55404
Minneapolis, Minnesota 55455
Site Public Contact
612-624-2620
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Jefferson City, Missouri 65109
Kansas City, Missouri 64108
Osage Beach, Missouri 65065
Saint Louis, Missouri 63110
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Missoula, Montana 59802
Omaha, Nebraska 68114
Site Public Contact
402-955-3949
Omaha, Nebraska 68198
Carson City, Nevada 89703
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89074
Henderson, Nevada 89074
Henderson, Nevada 89074
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Las Vegas, Nevada 89103
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89109
Las Vegas, Nevada 89113
Las Vegas, Nevada 89119
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89135
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89169
Pahrump, Nevada 89048
Reno, Nevada 89502
Reno, Nevada 89503
Reno, Nevada 89509
Lebanon, New Hampshire 03756
Hackensack, New Jersey 07601
Site Public Contact
201-996-2879
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
New Brunswick, New Jersey 08901
New Brunswick, New Jersey 08903
Site Public Contact
732-235-8675
Newark, New Jersey 07112
Paterson, New Jersey 07503
Albuquerque, New Mexico 87102
Albany, New York 12208
Site Public Contact
518-262-5513
Bronx, New York 10461
Bronx, New York 10461
Bronx, New York 10467
Bronx, New York 10467
Brooklyn, New York 11219
Site Public Contact
718-765-2500
Buffalo, New York 14263
Mineola, New York 11501
New Hyde Park, New York 11040
Site Public Contact
718-470-3460
New York, New York 10016
New York, New York 10029
New York, New York 10032
New York, New York 10065
Site Public Contact
212-639-7592
Rochester, New York 14642
Site Public Contact
585-275-5830
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Syracuse, New York 13210
Site Public Contact
315-464-5476
Valhalla, New York 10595
Site Public Contact
914-594-3794
Valhalla, New York 10595
Asheville, North Carolina 28801
Chapel Hill, North Carolina 27599
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28204
Clinton, North Carolina 28328
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Goldsboro, North Carolina 27534
Greenville, North Carolina 27834
Jacksonville, North Carolina 28546
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Fargo, North Dakota 58122
Akron, Ohio 44308
Site Public Contact
330-543-3193
Belpre, Ohio 45714
Chillicothe, Ohio 45601
Cincinnati, Ohio 45229
Cleveland, Ohio 44106
Cleveland, Ohio 44106
Site Public Contact
216-844-5437
Cleveland, Ohio 44195
Columbus, Ohio 43205
Columbus, Ohio 43213
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43219
Columbus, Ohio 43222
Columbus, Ohio 43228
Dayton, Ohio 45404
Site Public Contact
800-228-4055
Delaware, Ohio 43015
Delaware, Ohio 43015
Dublin, Ohio 43016
Dublin, Ohio 43016
Grove City, Ohio 43123
Lima, Ohio 45801
Site Public Contact
419-226-9617
Mansfield, Ohio 44903
Marietta, Ohio 45750
Marion, Ohio 43302
Marysville, Ohio 43040
Mount Vernon, Ohio 43050
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Sylvania, Ohio 43560
Toledo, Ohio 43606
Toledo, Ohio 43608
Toledo, Ohio 43623
Westerville, Ohio 43081
Wilmington, Ohio 45177
Site Public Contact
937-283-2273
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Bend, Oregon 97701
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Newberg, Oregon 97132
Oregon City, Oregon 97045
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97227
Site Public Contact
503-413-2560
Portland, Oregon 97239
Allentown, Pennsylvania 18103
Danville, Pennsylvania 17822
Hershey, Pennsylvania 17033
Site Public Contact
717-531-6012
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
Site Public Contact
800-474-9892
Philadelphia, Pennsylvania 19134
Site Public Contact
215-427-8991
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15224
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Boiling Springs, South Carolina 29316
Site Public Contact
864-241-6251
Charleston, South Carolina 29425
Columbia, South Carolina 29203
Site Public Contact
864-241-6251
Gaffney, South Carolina 29341
Greenville, South Carolina 29601
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Site Public Contact
864-241-6251
Greer, South Carolina 29650
Site Public Contact
864-241-6251
Greer, South Carolina 29651
Seneca, South Carolina 29672
Site Public Contact
864-241-6251
Spartanburg, South Carolina 29303
Site Public Contact
864-560-6812
Spartanburg, South Carolina 29303
Spartanburg, South Carolina 29307
Site Public Contact
864-560-6812
Union, South Carolina 29379
Sioux Falls, South Dakota 57117-5134
Chattanooga, Tennessee 37403
Site Public Contact
423-778-7289
Knoxville, Tennessee 37916
Site Public Contact
865-541-8266
Memphis, Tennessee 38105
Nashville, Tennessee 37203
Site Public Contact
615-342-1919
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Amarillo, Texas 79106
Site Public Contact
806-354-5411
Austin, Texas 78723
Corpus Christi, Texas 78411
Dallas, Texas 75230
Site Public Contact
972-566-5588
Dallas, Texas 75235
Dallas, Texas 75390
El Paso, Texas 79905
Fort Worth, Texas 76104
Houston, Texas 77030
Houston, Texas 77030
Lubbock, Texas 79410
Lubbock, Texas 79415
Site Public Contact
806-775-8590
San Antonio, Texas 78207
San Antonio, Texas 78229
San Antonio, Texas 78229
San Antonio, Texas 78229
Temple, Texas 76508
Site Public Contact
254-724-5407
Salt Lake City, Utah 84113
Site Public Contact
801-585-5270
Burlington, Vermont 05405
Charlottesville, Virginia 22908
Norfolk, Virginia 23507
Portsmouth, Virginia 23708-2197
Site Public Contact
757-953-5939
Richmond, Virginia 23298
Aberdeen, Washington 98520
Bellingham, Washington 98225
Site Public Contact
360-788-8223
Bremerton, Washington 98310
Centralia, Washington 98531
Edmonds, Washington 98026
Everett, Washington 98201
Issaquah, Washington 98029
Kennewick, Washington 99336
Lacey, Washington 98503
Longview, Washington 98632
Seattle, Washington 98105
Site Public Contact
866-987-2000
Seattle, Washington 98107
Seattle, Washington 98122-5711
Seattle, Washington 98122
Shelton, Washington 98584
Spokane, Washington 99204
Tacoma, Washington 98405
Tacoma, Washington 98431
Vancouver, Washington 98664
Walla Walla, Washington 99362
Yakima, Washington 98902
Yelm, Washington 98597
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Morgantown, West Virginia 26506
Green Bay, Wisconsin 54301-3526
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Johnson Creek, Wisconsin 53038
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53226
Oconto Falls, Wisconsin 54154
Sheboygan, Wisconsin 53081
Sturgeon Bay, Wisconsin 54235-1495
More Details
- NCT ID
- NCT03067181
- Status
- Recruiting
- Sponsor
- Children's Oncology Group
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate whether a strategy of complete surgical resection followed by surveillance can maintain an overall survival rate of at least 95.7% at two years for pediatric, adolescent and adult patients with stage I (low risk) malignant germ cell tumors, and at least 95% for patients with ovarian pure immature teratoma. II. To compare the event-free survival of a carboplatin versus (vs.) cisplatin-based regimen in the treatment of pediatric, adolescent and young adult patients with standard risk non-seminomatous germ cell tumors. IIa. To compare the event free survival (EFS) of a carboplatin-based regimen (carboplatin [C] etoposide [E] bleomycin [b]) vs. a cisplatin-based regimen (cisplatin [P]Eb) in children (less than 11 years in age) with standard risk germ cell tumors (GCT). IIb. To compare the EFS of a carboplatin-based regimen (BEC) vs. a cisplatin-based regimen (BEP) in adolescents and young adults (ages 11 - < 25 years) with standard risk GCT. SECONDARY OBJECTIVES: I. To compare the incidence of ototoxicity in children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy. II. To refine and validate a novel patient-reported measure of hearing outcomes for children, adolescents and young adults with standard risk germ cell tumors. EXPLORATORY OBJECTIVES: I. To prospectively determine the correlation of tumor marker decline (alpha-fetoprotein [FP] and beta-human chorionic gonadotropin [HCG]) with clinical outcome in low and standard risk germ cell tumor patients. II. To compare self-reported peripheral neuropathy and other patient-reported outcomes between children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy. III. Assess the relationship between hearing loss as measured by audiometry with the effects of tinnitus as assessed on the Adolescent and Young Adult Hearing Screening (AYA-HEARS) instrument. IV. To evaluate the prognostic significance of serum micro ribonucleic acid (miRNA)s in stage I testicular cancer (seminoma and non-seminoma) patients by collecting clinical data and serum specimens for future analysis. OUTLINE: Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma malignant germ cell tumors (MGCT)s undergo observation and can transfer to standard risk arm at time of recurrence if eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or chest x-ray as well as blood sample collection throughout the trial to monitor for response and recurrence. Patients may also undergo a tumor biopsy throughout the trial. Patients with standard risk 1 are randomized into 1 of 2 arms. ARM I (CEb): Patients receive bleomycin intravenously (IV) over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. ARM II (PEb): Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. Patients with standard risk 2 are randomized into 1 of 2 arms. ARM III (BEC): Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. ARM IV (BEP): Patients receive bleomycin IV over 10 minutes on days 1, 8, 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. After completion of study treatment, patients are followed up every 2 months for 12 months, every 3-6 months to 24 months, every 6 months for years 3-5, and then annually for up to 10 years.